Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799335 | 1.00 | AGER (0.44) | AGERMTNR1ACHRM2CHRM3ESR2 | |
| SCHEMBL6495515 | 0.91 | DPP4 (0.49) | AGERMTNR1ACHRM2CHRM3ESR2 | |
| SCHEMBL6495680 | 0.91 | DPP4 (0.49) | AGERMTNR1ACHRM2CHRM3ESR2 | |
| SCHEMBL6482118 | 0.87 | CCR5 (0.43) | AGERMTNR1ACHRM2CHRM3ESR2 | |
| SCHEMBL6482121 | 0.87 | CCR5 (0.43) | AGERMTNR1ACHRM2CHRM3ESR2 | |
| SCHEMBL3370759 | 0.84 | AGER (0.55) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL4801241 | 0.84 | HSD11B1 (0.48) | OPRM1UBE2MDCUN1D1 | |
| SCHEMBL4801250 | 0.84 | HSD11B1 (0.48) | OPRM1UBE2MDCUN1D1 | |
| SCHEMBL7245757 | 0.81 | TYR (0.54) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL7245773 | 0.81 | TYR (0.54) | AGERMTNR1ACHRM2CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7453010-B2 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-05-11 | — | — | US | disclosed |
| EP-1511722-A1 | PHENYLCYCLOHEXYLPROPANOLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099772-A1 | PHENYLCYCLOHEXYLPROPANOLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | CHRM1, CHRM2, C1R | AGER 2843/4885MTNR1A 101/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.